Get started
Author

Marc Bourgeois

Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb
2021 · Mona Khan, Seung-Jun Yoo, et al. · Cell · 392
PDF
Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study
2023 · Alexis Tabah, Niccolò Buetti, et al. · Intensive Care Medicine · 271
PDF
Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology
2021 · Juergen Prattes, Joost Wauters, et al. · Clinical Microbiology and Infection · 238
PDF
Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study
2016 · Ary Serpa Neto, Carmen S V Barbas, et al. · The Lancet Respiratory Medicine · 203
PDF
Multinational Observational Cohort Study of COVID-19–Associated Pulmonary Aspergillosis1
2021 · Nico A.F. Janssen, Rémy Nyga, et al. · Emerging infectious diseases · 136
PDF
ECMO for COVID-19 patients in Europe and Israel
2021 · Roberto Lorusso, Alain Combes, et al. · Intensive Care Medicine · 120
PDF
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
2022 · Jean Chastre, Bruno François, et al. · Critical Care · 107
PDF
Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial
2021 · Lore Vanderbeke, Nico A. F. Janssen, et al. · Intensive Care Medicine · 103
PDF
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
2021 · Bruno François, Hasan S Jafri, et al. · The Lancet Infectious Diseases · 100
In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study
2022 · Roberto Lorusso, Maria Elena De Piero, et al. · The Lancet Respiratory Medicine · 89
Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry
2021 · Juergen Prattes, Joost Wauters, et al. · Intensive Care Medicine · 55
PDF
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
2024 · Marine Maurel, Jennifer Howard, et al. · Eurosurveillance · 50
PDF
Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies
2021 · Luigi Pisani, Anna Geke Algera, et al. · The Lancet Global Health · 49
PDF
COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges
2021 · Juergen Prattes, Philipp Koehler, et al. · Intensive Care Medicine · 44
PDF
Impact of a VAP bundle in Belgian intensive care units
2018 · Laurent Jadot, Luc Huyghens, et al. · Annals of Intensive Care · 36
PDF
Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion
2013 · J.J. De Waele, I. Danneels, et al. · International Journal of Antimicrobial Agents · 34
Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Post Hoc Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study
2022 · Daniele Roberto Giacobbe, Juergen Prattes, et al. · Journal of Clinical Microbiology · 31
Treatment With the Platelet-activating Factor Antagonist Tcv-309 in Patients With Severe Systemic Inflammatory Response Syndrome: a Prospective, Multi-center, Doubleblind, Randomized Phase Ii Trial;
1996 · Albert M.F. Froon, Jan Willem M. Greve, et al. · Shock · 31
Pharmacologic treatment of acute renal failure in sepsis
2003 · An S. De Vriese, Marc Bourgeois · Current Opinion in Critical Care · 29
Post-influenza aspergillosis, do not underestimate influenza B
2017 · Eric FL Nulens, Marc JC Bourgeois, et al. · Infection and Drug Resistance · 28
PDF
Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015–20: a surveillance study
2021 · Natalie Fischer, Nicolas Dauby, et al. · The Lancet Microbe · 24
PDF
Pulmonary Aspergillosis in Critically Ill Coronavirus Disease 2019 Patients– A Multinational Observational Study by the European Confederation of Medical Mycology
2021 · Juergen Prattes, Joost Wauters, et al. · SSRN Electronic Journal · 21
635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti- Pseudomonas aeruginosa Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) Program
2020 · Jean Chastre, Bruno François, et al. · Open Forum Infectious Diseases · 21
Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19
2020 · Lorenzo Subissi, Nathalie Bossuyt, et al. · Eurosurveillance · 19
PDF
The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
2024 · Niccolò Buetti, Alexis Tabah, et al. · Intensive Care Medicine · 18
Works count: 53
Citation count: 2,315
H-index: 21
I10-index: 28
Year
Topic
Type